Cogent Biosciences Inc
$ 38.94
-0.79%
16 Jan - close price
- Market Cap 5,977,507,000 USD
- Current Price $ 38.94
- High / Low $ 41.35 / 38.59
- Stock P/E N/A
- Book Value 1.39
- EPS -2.05
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.48 %
- ROE -0.95 %
- 52 Week High 43.73
- 52 Week Low 3.72
About
Cogent Biosciences, Inc. is a leading biotechnology firm based in Cambridge, Massachusetts, focused on the development of precision therapies for genetically defined diseases. Leveraging its proprietary technology platform, Cogent aims to address specific genetic mutations with targeted therapeutic solutions that enhance patient outcomes. The company boasts a robust pipeline of innovative treatments, positioning itself at the forefront of the precision medicine revolution. As it continues to drive advancements in its field, Cogent represents a compelling investment opportunity for institutional investors seeking significant growth within the biopharmaceutical landscape.
Analyst Target Price
$50.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-17 | 2025-08-05 | 2025-05-05 | 2025-02-24 | 2024-10-31 | 2024-08-06 | 2024-05-07 | 2024-02-26 | 2023-11-02 | 2023-08-08 | 2023-05-09 | 2023-03-14 |
| Reported EPS | -0.5 | -0.595 | -0.5249 | -0.09 | -0.6412 | -0.59 | -0.62 | -0.63 | -0.64 | -0.59 | -0.54 | -0.56 |
| Estimated EPS | -0.5229 | -0.5867 | -0.5771 | -0.5837 | -0.5664 | -0.56 | -0.52 | -0.56 | -0.5 | -0.54 | -0.57 | -0.52 |
| Surprise | 0.0229 | -0.0083 | 0.0522 | 0.4937 | -0.0748 | -0.03 | -0.1 | -0.07 | -0.14 | -0.05 | 0.03 | -0.04 |
| Surprise Percentage | 4.3794% | -1.4147% | 9.0452% | 84.5811% | -13.2062% | -5.3571% | -19.2308% | -12.5% | -28% | -9.2593% | 5.2632% | -7.6923% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.51 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: COGT
2026-01-16 07:57:48
Cogent Biosciences' stock rose 10.3% after outlining its 2026 strategy for bezuclastinib, including multiple New Drug Application submissions for systemic mastocytosis and gastrointestinal stromal tumors. The company also plans to expand its precision oncology pipeline with new IND filings and commercial leadership hires, signaling a sharpened focus on bringing bezuclastinib to market. Despite its pre-revenue status and high valuation, the roadmap highlights near-term catalysts, though funding and execution risks remain.
2026-01-15 21:12:00
This article analyzes Cogent Biosciences Inc. (COGT) using AI models to generate trading strategies. It identifies varying sentiment across different time horizons—positive near-term, weak mid-term, and strong long-term—and provides specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The analysis also highlights support and resistance levels across multiple timeframes.
2026-01-15 09:59:34
Cogent Biosciences (COGT) has gained significant attention following its FDA New Drug Application submission for bezuclastinib, supported by strong trial data and a Breakthrough Therapy Designation. The stock has seen a substantial price increase, now trading at $35.57, which is about 41% below the average analyst target. However, its high Price-to-Book ratio of 27.8x suggests it may be overvalued compared to peers, reflecting high market expectations for its pipeline.
2026-01-14 03:29:11
Cogent Biosciences has announced its anticipated commercial and clinical milestones for 2026, focusing on bezuclastinib and its precision therapies portfolio. Key plans include submitting New Drug Applications (NDAs) for bezuclastinib in multiple indications like NonAdvSM, AdvSM, and GIST, with potential commercial launch in the second half of 2026. The company also expects to submit Investigational New Drug (IND) applications for novel pan-KRAS(ON) and JAK2 V617F inhibitors, supported by a strong financial position of approximately $900 million.
2026-01-12 15:27:30
Cogent Biosciences has announced its anticipated commercial and clinical milestones for 2026, including plans to submit several New Drug Applications (NDAs) for bezuclastinib in various indications, with commercialization expected in the second half of the year. The company also intends to file Investigational New Drug (IND) applications for new pan-KRAS(ON) and JAK2 V617F inhibitors. Cogent Biosciences is in a strong financial position with approximately $900 million in cash, sufficient to fund operations and product launches into 2028.
2026-01-12 13:29:23
Cogent Biosciences (NASDAQ: COGT) has announced its commercial and clinical objectives for 2026, focusing on bezuclastinib and its precision therapies pipeline. Key actions include NDA submissions for various indications, presentations of pivotal trial data, and IND submissions for new inhibitors. The company also reported a strong cash balance of approximately $900 million at the start of 2026, supporting its planned commercial launch and operations.
